AUTHORS
Nicole Vincelette, PhD, Qianxing Mo, PhD2, Chia-Ho Cheng, PhD3, Junyoung Park, PhD4, Andrew T Kuykendall, MD5, Ling Zhang, MD6, Jungwon Moon7, Tiffany Razabdouski, B.S.8, Erika Adriana Eksioglu, PhD9, Felyschia Lledo10, Peter R Papenhausen, PhD11, Zhuoer Xie, MD,MS12, Onyee Chan, MD13, David Sallman, MD14, Javier Pinilla-Ibarz, MD PhD15, Daniel J Murphy, PhD16, Rami Komrokji, MD17, John L Cleveland, PhD18, Xiaoqing Yu, PhD19, Seongseok Yun, MD, PhD20
AFFILIATIONS
1 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
16 University of Glasgow, Glasgow, United Kingdom
17 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
20 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Introduction: Mosaic chromosomal alterations (mCAs), including gains (+), losses (-), and copy-number-neutral loss of heterozygosity (CNLOH; =), constitute a prevalent form of clonal hematopoiesis (CH) affecting 10-40% of individuals over age 70, yet their clinical consequences beyond hematologic malignancy remain poorly defined. Two questions are unresolved: whether mCAs confer disease risk independently of clonal hematopoiesis of indeterminate potential (CHIP), and whether alterations spanning hundreds of genes can be resolved to individual effector genes.
Methods: We analyzed 452,594 UK Biobank participants using SNP-array-derived mCA calls (Loh et al. 2020). Incident disease and cause-specific mortality were ascertained from linked inpatient and death-registry ICD-10 records with death treated as a competing event (Gray's test, Fine-Gray regression). Disease-associated cytobands within heterogeneous mCAs were prioritized by LASSO-penalized Cox regression and refit in standard Cox models. Candidate effector genes were nominated by 5' single-cell RNA sequencing of bone marrow mononuclear cells from patients with chromosome 8 gain (8+) or chromosome 1 gain (1+) vs. healthy donors, with per-cell copy number inferred by Numbat and locus-level transcriptional activity by InferCNV, and tested in vivo in Mx1-Cre;Rosa26-LSL-MYC and S100A9Tg mice.
Results: 42,390 participants (9.4%) harbored at least 1 mCA, comprising 45,536 events (5.6% gains, 76.2% losses, 18.2% CNLOH). Carriers were older (OR=1.12), more often male (OR=2.67), had higher white blood cell counts (OR=2.25, all p<0.0001), with elevated circulating pro-inflammatory cytokines and alarmins. Carriers developed more incident disease (HR=1.33) and required more hospital admissions (HR=1.39, both p<0.0001), with elevated risk across nearly all ICD-10 chapters (HRs=1.02-1.20, all p<0.05); the broadest associations were seen for 3+, 8+, 9=, 12+, and Y-. Risk scaled with mosaic cell fraction (MCF) in both binned and spline models.
mCAs independently predicted all-cause mortality (HR=1.21, p<0.0001), graded by complexity (complex HR=3.11; gain-only 1.44; CNLOH-only 1.30; loss-only 1.16) and by clonal burden (high vs low MCF, HR=1.40 vs 1.10). Cause-specific analyses showed excess mortality across multiple organ systems, with cardiovascular death elevated despite unchanged cardiovascular incidence. Among 404,468 participants without CHIP, mCAs remained associated with shorter overall survival (HR=1.17, p<0.0001). Joint stratification showed no interaction for disease incidence, but a significant positive interaction for mortality (mCA+/CHIP+ HR=1.87; interaction HR=1.16, p=0.0045), defining a very high-risk clonal state not captured by CHIP screening alone.
Because mCAs span hundreds of genes, causal testing requires first nominating candidates within them. Our cytoband mapping localized risk to discrete loci, including gains at 1q21-23, 3q11-26, and 8q21-24; losses at 5q13-33, 7q21-36, and 17p11-13; and CNLOH at 4q21-31, 9p21-24, and 13q12-22, with gain-associated regions enriched for oncogenes and inflammatory mediators. Intersecting 723 genes differentially expressed in 8+ hematopoietic stem cells with chromosome 8 loci yielded 40 candidates, of which MYC ranked highest within the LASSO-selected 8q21.3-24.23 region; the parallel analysis in 1+ cells prioritized S100A9 within 1q21.1-23.2.
Supporting causality, hematopoietic MYC overexpression in mice provoked monocytosis, anemia, hematopoietic stem and progenitor cell expansion, fibrosis of marrow, spleen, liver, and heart, and shortened survival, recapitulating features of 8+ carriers, who showed monocytosis, anemia, and reduced survival. S100A9 overexpression produced comparable multiorgan fibrosis and survival loss.
Conclusions: mCAs are independent, dose-dependent, and CHIP-synergistic drivers of age-related multimorbidity and mortality. Cytoband-level mapping converts large structural events into tractable effector genes, with MYC and S100A9 converging on inflammation as a shared mechanism of multiorgan disease. These findings argue for incorporating mCA assessment into CH risk stratification and identify inflammatory effector pathways as candidate therapeutic targets.
DISCLOSURES
Seongseok Yun, MD, PhD: No relevant conflicts of interest to declare.